Hexarelin (Examorelin)

Comprehensive Research Analysis - Potent Growth Hormone Secretagogue with Cardioprotective Properties

Classification: Growth Hormone-Releasing Peptide (GHRP), GHS-R1a Agonist Amino Acid Sequence: His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂ Chemical Formula: C₄₇H₅₈N₁₂O₆ Molecular Weight: 887.04 Da Research Status: Extensive preclinical and Phase II clinical trials WADA Status: PROHIBITED - S2 Peptide Hormones, Growth Factors

1. Executive Summary

Hexarelin (examorelin) is a synthetic hexapeptide and potent agonist of the growth hormone secretagogue receptor (GHS-R1a), developed from GHRP-6 with enhanced stability and receptor affinity. This six-amino-acid peptide is one of the most potent GH secretagogues available, offering longer half-life and sustained activity compared to GHRP-2 or GHRP-6.

Unique Dual Mechanism: While hexarelin powerfully stimulates growth hormone release via GHS-R1a (ghrelin receptor), it also demonstrates growth hormone-independent cardioprotective effects mediated by cardiac CD36 receptors. This cardioprotective action prevents cardiac damage after ischemia-reperfusion injury independent of GH elevation.

Clinical Evidence: Human dose-response studies demonstrated ED50 of 0.50 μg/kg for maximum GH concentration. Hexarelin was well-tolerated in all subjects, though long-term safety data remain limited.

Goal Archetype Integration

Primary Goal Alignment

When Hexarelin Makes Sense

• Primary goal is cardiac protection - Hexarelin's CD36-mediated cardioprotective effects are unique among GHRPs and operate independently of GH release
• Maximum GH release is the priority - Hexarelin is one of the most potent GH secretagogues available
• History of ischemic heart disease - Research demonstrates protection against ischemia-reperfusion injury
• Post-cardiac event recovery - Single oral dose protected chronic cardiac function after MI in mice
• Willing to cycle strictly - Required 4-6 week breaks every 12-16 weeks to prevent desensitization
• Can tolerate mild prolactin/cortisol elevation - Unlike Ipamorelin, Hexarelin does elevate these hormones

When to Choose Something Else

2. Chemical Structure & Composition

Molecular Weight: 887.04 Da Formula: C₄₇H₅₈N₁₂O₆

Amino Acid Sequence: His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂

Structural Modifications:

1. D-amino acids: D-2-methyl-tryptophan at position 2 and D-phenylalanine at position 5 increase stability, bioavailability, and GHS-R1a binding affinity
2. 2-methyl-tryptophan: Methyl group addition enhances receptor binding
3. C-terminal amidation: Further enhances biological activity

Development: Developed from GHRP-6 by addition of two methyl groups to enhance stability and receptor affinity. More stable and potent than natural ghrelin.

Alternative Names: Examorelin, HEX

3. Mechanism of Action

Dual Receptor System

Hexarelin operates through two distinct receptor pathways:

1. GHS-R1a (Ghrelin Receptor) - Growth Hormone Release

Primary mechanism for GH secretion:

• Binds and activates GHS-R1a in pituitary and hypothalamus
• Stimulates pulsatile GH release
• More potent than GHRP-2, GHRP-6, and natural ghrelin
• Longer half-life than other GHRPs

Downstream Effects:

• Increased IGF-1 production in liver
• Enhanced protein synthesis
• Lipolysis (fat breakdown)
• Muscle growth and recovery

2. CD36 Receptor - Cardioprotection (GH-Independent)

Unique cardiovascular mechanism:

• CD36 is a multifunctional glycoprotein expressed in cardiomyocytes and microvascular endothelial cells
• Hexarelin binds directly to cardiac CD36 receptors
• Prevents cardiac damage after ischemia-reperfusion injury
• Action NOT mediated by growth hormone

Cardioprotective Mechanisms:

• Inhibits cardiomyocyte apoptosis
• Promotes cell survival after ischemia
• Positive inotropic effect on ischemic cardiomyocytes
• Protects from ischemia-reperfusion injury

Additional Hormonal Effects

Slight increases in prolactin, cortisol, and ACTH, though hexarelin does not raise cortisol or prolactin as much as other GHRPs, making it more favorable for long-term use.

4. Pharmacokinetics

Half-Life:

• Human: ~55 minutes plasma half-life
• Dog: 120 minutes terminal half-life (IV)
• Rat: 75.9 ± 9.3 minutes (IV)

Time to Peak: ~30 minutes for maximum GH concentration in humans, with GH returning to baseline within 240 minutes

Oral Bioavailability: 0.3 ± 0.1% (extremely low) - attributed to:

• Poor intestinal permeability
• Degradation in presence of intestinal contents
• Metabolite identified as hexarelin deamidated at lysine residue

Distribution (Rat IV):

• Clearance: 7.6 ± 0.7 ml/min/kg
• Volume of Distribution (Vdss): 744 ± 81 ml/kg

Distribution (Dog IV):

• Vdss: 387.7 ml/kg
• Clearance: 4.28 ml/min/kg

Intestinal Permeability: Low permeability across rat ileum and Caco-2 cell monolayers, contributing to poor oral absorption

Metabolism: Primarily proteolytic degradation, with deamidation at lysine residue as major pathway

5. Dosing Protocols

Human Clinical Trials (Intravenous)

Dose-Response Studies:

• Range: 0.5, 1.0, 2.0 μg/kg single IV bolus
• ED50: 0.50 μg/kg (maximum GH concentration)
• ED50: 0.64 μg/kg (area under curve)
• Optimal Dose: 1.0 μg/kg - used in majority of studies
• Maximum Response: GH plateau of 140 mU/L at 1.0 μg/kg

Research/Experimental Subcutaneous Protocols

Note: Following protocols are research-based and NOT FDA-approved:

• Typical Range: 100-200 mcg per injection
• Frequency: 2-3 times daily (morning, post-workout, bedtime)
• Cycling: 16 weeks treatment with 4-week break
• Desensitization Note: Marked decrease in endogenous GH production after 16 weeks; partial desensitization reversible after 4-week break

Administration

Route: Intravenous (clinical trials) or subcutaneous (research) Timing: Typically administered on empty stomach for optimal GH response Sites (SC): Abdomen, thigh (rotate injection sites)

CRITICAL: Due to 0.3% oral bioavailability, oral administration is ineffective. Injectable routes required.

Age-Stratified Dosing

Critical Context: Hexarelin's GH-releasing efficacy varies significantly by age. GH response is powerful in pubertal children and young adults but blunted in prepubertal children and elderly subjects.

Age-Related Optimization Strategies:

1. Elderly subjects: Arginine potentiates GH response to hexarelin in elderly but not young subjects - consider 5-9g arginine 30 min pre-dose
2. Higher body fat: Increasing total fat mass blunts GH response - optimize body composition or increase dose
3. GHRH combination: GHRH restores blunted GH-releasing activity in elderly

Desensitization & Cycling Requirements

CRITICAL - Mandatory Cycling: Unlike Ipamorelin, Hexarelin requires strict cycling to maintain efficacy.

Comparison with Ipamorelin:

• Hexarelin: Must cycle 12-16 weeks on / 4-6 weeks off
• Ipamorelin: Can be used more continuously with less desensitization concern
• Rationale: Hexarelin's higher potency appears to cause faster receptor downregulation

Sex-Specific Considerations

Males:

• Standard dosing protocols apply
• Monitor prolactin more closely - hexarelin elevates prolactin (risk: reduced libido, gynecomastia)
• Consider dopamine agonist support if prolactin symptoms emerge

Females:

• Same dosing as males (weight-based when using µg/kg)
• GH response patterns similar between sexes in clinical trials
• Menstrual cycle: No specific timing requirements identified in literature
• Pregnancy/breastfeeding: Contraindicated (insufficient safety data)

6. Clinical Research & Evidence

Human Growth Hormone Studies

Dose-Response Trial (N=12 adult males):

• Single IV boluses: 0.5, 1, 2 μg/kg
• ED50: 0.50 μg/kg (maximum GH)
• ED50: 0.64 μg/kg (AUC)
• Conclusion: Hexarelin well-tolerated in all subjects

Hormonal Release Study:

• Doses: 0-1.0 μg/kg IV in healthy adult males
• GH dose-response plateau: 140 mU/L at 1.0 μg/kg
• ED50: 0.48 ± 0.02 μg/kg
• Side Effects: Slight increase in prolactin, cortisol, ACTH

Repeated Administration Study:

• 16-week treatment period
• Observed partial desensitization to GH response
• 4-week break restored GH response to near-baseline
• Implication: Cycling necessary to maintain efficacy

Cardiovascular Studies

Growth Hormone-Independent Cardioprotection (Rat):

• Hexarelin prevented cardiac damage after ischemia-reperfusion
• Effects NOT mediated by GH
• Mediated via cardiac CD36 receptors

Single Dose Oral Cardioprotection (Mouse):

• One dose of oral hexarelin protected chronic cardiac function after myocardial infarction
• Despite low oral bioavailability, cardioprotective effects observed

CD36 Receptor Identification:

• CD36 identified as specific cardiac hexarelin receptor
• Expressed in cardiomyocytes and microvascular endothelial cells
• Mediates cardiovascular actions independent of GH

Comparative Potency

Hexarelin is more stable and potent than natural ghrelin. Longer half-life and sustained activity vs GHRP-2 or GHRP-6.

7. Safety Profile

Common Side Effects

Dose-dependent, minimal, reversible:

Physical Symptoms:

• Water retention and bloating (due to increased GH)
• Increased appetite (ghrelin mimicry)
• Joint pain and swelling (GH/IGF-1 elevation)
• Flushing, headache, dizziness
• Injection site reactions

Hormonal Effects:

• Raised prolactin and cortisol levels (less than other GHRPs)
• Changes in blood glucose levels - diabetic monitoring required
• Sleep pattern changes - insomnia or vivid dreams

Serious Concerns

Tumor Growth Potential: Primary concern is potential to promote tumor growth in individuals with cancer history, due to IGF-1 elevation.

Cardiovascular Effects: Changes in blood pressure and cardiac function observed (though cardioprotective effects also documented).

Desensitization: Marked decrease in endogenous GH production after 16-week treatment; reversible with 4-week break.

Overall Safety

Favorable safety profile when administered properly. Well-tolerated in most cases. Does NOT cause androgenization following steroid abuse.

CRITICAL: Long-term safety data limited. Clinical trials to extend application and observe long-term effects are warranted.

Drug Interactions - Comprehensive

CRITICAL: Hexarelin vs Ipamorelin Hormone Profile

This is the most important differentiation when selecting between GHRPs:

Clinical Implications:

• Ipamorelin is the first selective GHS - does not affect ACTH or cortisol even at 200x the ED50 for GH
• Hexarelin's prolactin-releasing activity is lower than TRH but ACTH/cortisol activity is similar to hCRH
• For hormone-sensitive individuals, Ipamorelin is the safer choice

Synergistic Combinations

Prescription Medication Interactions

Other Peptide Interactions

Supplements

Foods & Timing Interactions

8. Administration & Practical Application

Route: Intravenous (clinical) or subcutaneous (research) Sites (SC): Abdomen, thigh (rotate) Reconstitution: Typically reconstituted with bacteriostatic water Injection Technique:

• Inject slowly
• Use insulin syringes for SC administration
• Alcohol swab injection site

Timing Considerations:

• Empty stomach for optimal GH response
• Post-workout or bedtime common timing
• Avoid food 1-2 hours before/after

Storage After Reconstitution:

• Refrigerate 2-8°C
• Use within 14-30 days (varies by formulation)
• Protect from light

Clinical Monitoring:

• Baseline: GH, IGF-1, glucose, lipids
• Ongoing: Monitor for water retention, joint pain, glucose changes
• Cancer screening if history of malignancy

Bloodwork Impact & Monitoring

Expected Marker Changes

Monitoring Schedule

Red Flags in Labs

Labs + Symptoms Integration

Marker-Based Dose Adjustment

Adjustment by Baseline Markers

Adjustment by Response Markers

9. Storage & Stability

Lyophilized Powder (Unreconstituted):

• Store at -20°C (freezer) for long-term stability
• Can store 2-8°C (refrigerator) short-term
• Protect from light and moisture

Reconstituted Solution:

• Refrigerate 2-8°C
• Use within 14-30 days
• Do not freeze
• Protect from light

Stability Notes: D-amino acids and methylation enhance stability vs unmodified peptides, but still requires proper cold storage.

11. Product Cross-Reference

Core Peptides Equivalent: Product page inaccessible during research; verify availability directly at https://www.corepeptides.com/product/hexarelin/

Typical Research Chemical Specifications:

• Purity: >98% (HPLC verified)
• Form: Lyophilized powder
• Sizes: 2mg, 5mg, 10mg vials

Epiq Aminos: Product availability and pricing to be confirmed via https://orange-shrew-635172.hostingersite.com/

IMPORTANT: Due to NOT FDA-approved status, all hexarelin products are research chemicals. Quality and purity vary significantly between suppliers. Analytical testing recommended before use.

Athletes: Complete prohibition under WADA Code. Use results in anti-doping violations.

Protocol Integration

Hexarelin vs Ipamorelin: Decision Framework

Choose Hexarelin when:

Choose Ipamorelin when:

Stacking with Other Compounds

Common Stacks

Stacks to Avoid

Timing Considerations

Integration with Lifestyle Pillars

Sample Protocols

Protocol A: Maximum GH Release (8-12 weeks)

Goal: Aggressive body recomposition, maximum anabolic effect

Protocol B: Cardiac Protection Focus (12-16 weeks)

Goal: Cardiovascular protection, moderate GH benefits

Protocol C: Elderly Optimization (rotating)

Goal: Restore age-related GH decline

Clinical Insights - Practitioner Dosing

Source: YouTube practitioner interviews

• High dosages of bpc 157 the typical therapeutic doses that are prescribed are anywhere from 300 to 500 micrograms subcutaneously maybe two or three times per week and that is typically done for a cou
• t I made earlier which is that bpc 157 is typically taken in these dosages of about 300 to 500 micrograms two to three times per week maybe even five days per week if you're going to

Stacking Insights

• irtue of acronyms and numbers bpc 157 or mk677 etc such that if you're not really familiar with them it can be a bit overwhelming and Confused today I'm going to provide a very simple organiz
• mental health goals I'd be remiss if I didn't say at the outset here that a lot of what's happening with applied therapeutic peptide biology falls into one of three categories there are peptides that

12. References & Citations

1. Examorelin - Wikipedia
2. Swolverine - Unlocking the Power of Hexarelin
3. Ghigo E, et al. Growth hormone-releasing activity of hexarelin in humans. Eur J Clin Pharmacol. 1994.
4. Rahim A, et al. Hexarelin-induced GH, cortisol, and prolactin release. J Clin Endocrinol Metab. 1996.
5. Locatelli V, et al. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology. 1999.
6. Bodart V, et al. CD36 mediates cardiovascular action of GH-releasing peptides. Circulation Research. 2002.
7. Tivesten Å, et al. The cardiovascular action of hexarelin. Endocrine. 2014.
8. Okada K, et al. Kinetics and disposition of hexarelin in rats. Drug Metab Dispos. 2000.
9. Westberg E, et al. Hexarelin--evaluation of oral bioavailability. J Pharm Pharmacol. 2001.
10. Peptides.org - Hexarelin Reviews & Safety
11. WADA - Prohibited List
12. Core Peptides - Hexarelin vs GHRP-6

Document Version: 1.0 Last Updated: December 23, 2025 Development Status: Research Chemical; NOT FDA-Approved Regulatory Status: WADA Prohibited (S2)